Cytomegalovirus in solid organ transplant recipients: Clinical updates, challenges and future directions

Research output: Contribution to journalArticle

Abstract

Cytomegalovirus is the classic opportunistic infection after solid organ transplantation. This review will discuss updates and future directions in the diagnosis, prevention and treatment of CMV infection in solid organ transplant recipients. Antiviral prophylaxis and pre-emptive therapy are the mainstays of CMV prevention, but they should not be mutually exclusive and each strategy should be considered depending on a specific situa-tion. The lack of a widely applicable viral load threshold for diagnosis and preemptive therapy is emphasized as a major factor that should pave the way for an individualized approach to prevention. Valganciclovir and intravenous ganciclovir remain as drugs of choice for CMV management, and strategies for managing drug-resistant CMV infection are enumerated. There is increasing use of CMV-specific cell-mediated immune assays to stratify the risk of CMV infection after solid organ transplantation, and their potential role in optimizing CMV prevention and treatment efforts is discussed.

Original languageEnglish (US)
Pages (from-to)3497-3506
Number of pages10
JournalCurrent pharmaceutical design
Volume26
Issue number28
DOIs
StatePublished - 2020

Keywords

  • Cidofovir
  • Cytomegalovirus
  • Foscarnet
  • Ganciclovir
  • Transplantation
  • Valganciclovir

ASJC Scopus subject areas

  • Pharmacology
  • Drug Discovery

Fingerprint Dive into the research topics of 'Cytomegalovirus in solid organ transplant recipients: Clinical updates, challenges and future directions'. Together they form a unique fingerprint.

  • Cite this